Table 2. Oxidative stress markers at study baseline and 12-week after the intervention in patients who received either Co-Q10 or placebo.
| Variables | Co-Q10 (n = 39) | Placebo (n = 38) | MD (95% CI), p value | |
|---|---|---|---|---|
| TAC (mmol/L) | ||||
| Before | 1.52 ± 0.24 | 1.52 ± 0.27 | −0.004 (−0.11, 0.12), 0.950† | |
| After | 1.57 ± 0.28 | 1.51 ± 0.28 | −0.07 (−0.16, 0.02), 0.106‡ | |
| MD (95% CI) | 0.05 (−0.01, 0.11) | −0.01 (−0.07, 0.05) | ||
| p value* | 0.087 | 0.683 | ||
| MDA (nmol/mL) | ||||
| Before | 1.66 ± 0.57 | 1.63 ± 0.46 | −0.03 (−0.26, 0.21), 0.818† | |
| After | 1.53 ± 0.50 | 1.79 ± 0.55 | 0.30 (0.08, 0.52), 0.009‡ | |
| MD (95% CI) | −0.13 (−0.30, 0.03) | 0.16 (−0.02, 0.33) | ||
| p value* | 0.118 | 0.077 | ||
Data are expressed as mean ± standard deviation.
Co-Q10, Coenzyme Q10; MD, mean difference; CI, confidence interval; TAC, total antioxidant capacity; MDA, malondialdehyde.
*The p value is reported based on the analysis of paired t-test.
†Reported based on the analysis of independent sample t-test.
‡Reported based on the analysis of covariance adjusted for baseline values and also confounder variables (included age, years with migraine, changes in body mass index, body fat, physical activity and uptake of vitamin C and E and selenium).